AU2004275876B2 - Nucleic acid-lipophilic conjugates - Google Patents

Nucleic acid-lipophilic conjugates Download PDF

Info

Publication number
AU2004275876B2
AU2004275876B2 AU2004275876A AU2004275876A AU2004275876B2 AU 2004275876 B2 AU2004275876 B2 AU 2004275876B2 AU 2004275876 A AU2004275876 A AU 2004275876A AU 2004275876 A AU2004275876 A AU 2004275876A AU 2004275876 B2 AU2004275876 B2 AU 2004275876B2
Authority
AU
Australia
Prior art keywords
seq
composition
cancer
lipophilic
nucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004275876A
Other languages
English (en)
Other versions
AU2004275876A1 (en
Inventor
Arthur M. Krieg
Eugen Uhlmann
Joerg Vollmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Coley Pharmaceutical GmbH
Coley Pharmaceutical Group Inc
Original Assignee
Coley Pharmaceutical GmbH
Coley Pharmaceutical Group Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coley Pharmaceutical GmbH, Coley Pharmaceutical Group Inc filed Critical Coley Pharmaceutical GmbH
Publication of AU2004275876A1 publication Critical patent/AU2004275876A1/en
Application granted granted Critical
Publication of AU2004275876B2 publication Critical patent/AU2004275876B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2004275876A 2003-09-25 2004-09-27 Nucleic acid-lipophilic conjugates Ceased AU2004275876B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50597703P 2003-09-25 2003-09-25
US60/505,977 2003-09-25
PCT/US2004/031748 WO2005030259A2 (en) 2003-09-25 2004-09-27 Nucleic acid-lipophilic conjugates

Publications (2)

Publication Number Publication Date
AU2004275876A1 AU2004275876A1 (en) 2005-04-07
AU2004275876B2 true AU2004275876B2 (en) 2011-03-31

Family

ID=34393097

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004275876A Ceased AU2004275876B2 (en) 2003-09-25 2004-09-27 Nucleic acid-lipophilic conjugates

Country Status (6)

Country Link
US (2) US7615539B2 (enExample)
EP (1) EP1663316A2 (enExample)
JP (1) JP4989225B2 (enExample)
AU (1) AU2004275876B2 (enExample)
CA (1) CA2536139A1 (enExample)
WO (1) WO2005030259A2 (enExample)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US7935675B1 (en) * 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5981501A (en) * 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
EP0855184A1 (en) * 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AU733310C (en) * 1997-05-14 2001-11-29 University Of British Columbia, The High efficiency encapsulation of charged therapeutic agents in lipid vesicles
EP1067956B1 (en) * 1998-04-03 2007-03-14 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
ATE305507T1 (de) * 1998-05-14 2005-10-15 Coley Pharm Gmbh Verfahren zur regulierung der hematopoiese mit hilfe von cpg oligonukleotide
CA2328894A1 (en) 1998-05-22 1999-12-02 Loeb Health Research Institute At The Ottawa Hospital Methods and products for inducing mucosal immunity
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
EP1150710B1 (en) 1999-02-17 2010-04-21 Csl Limited Immunogenic complexes and methods relating thereto
DE60015084T2 (de) * 1999-02-26 2006-02-16 Chiron S.R.L. Verbesserung der bakterizidaktivität von neisseria antigenen mit cg enthaltende oligonukleotiden
NZ517929A (en) * 1999-09-25 2004-02-27 Univ Iowa Res Found Immunostimulatory nucleic acids
US6949520B1 (en) * 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
NZ520976A (en) * 1999-11-19 2005-01-28 Csl Ltd Vaccine compositions
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
US20040131628A1 (en) * 2000-03-08 2004-07-08 Bratzler Robert L. Nucleic acids for the treatment of disorders associated with microorganisms
DE60139689D1 (de) * 2000-06-22 2009-10-08 Univ Iowa Res Found Kombination von CpG und Antikörpern gegen CD19,CD20,CD22 oder CD40 zur Prävention oder Behandlung von Krebs.
WO2002022809A2 (en) * 2000-09-15 2002-03-21 Coley Pharmaceutical Gmbh PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST
US7785610B2 (en) * 2001-06-21 2010-08-31 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same—III
DK2423335T3 (da) * 2001-06-21 2014-08-18 Dynavax Tech Corp Kimæriske immunmodulatoriske forbindelser og fremgangsmåder til anvendelse deraf
JP4383534B2 (ja) 2001-08-17 2009-12-16 コーリー ファーマシューティカル ゲーエムベーハー 改善した活性を有する組み合わせモチーフ免疫刺激オリゴヌクレオチド
US20030139364A1 (en) * 2001-10-12 2003-07-24 University Of Iowa Research Foundation Methods and products for enhancing immune responses using imidazoquinoline compounds
US7276489B2 (en) * 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
JP2005516897A (ja) * 2001-11-07 2005-06-09 イネックス ファーマシューティカルズ コーポレイション 改善された粘膜のワクチン及びその使用方法
WO2003086280A2 (en) 2002-04-04 2003-10-23 Coley Pharmaceutical Gmbh Immunostimulatory g,u-containing oligoribonucleotides
US20040009944A1 (en) * 2002-05-10 2004-01-15 Inex Pharmaceuticals Corporation Methylated immunostimulatory oligonucleotides and methods of using the same
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) * 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
CN101948835A (zh) * 2002-10-29 2011-01-19 科勒制药集团股份有限公司 Cpg寡核苷酸在治疗丙型肝炎病毒感染中的应用
AU2003300919A1 (en) 2002-12-11 2004-06-30 Coley Pharmaceutical Gmbh 5' cpg nucleic acids and methods of use
US7354907B2 (en) * 2003-02-07 2008-04-08 Idera Pharmaceuticals, Inc. Short immunomodulatory oligonucleotides
WO2004091572A2 (en) * 2003-04-09 2004-10-28 Biodelivery Sciences International, Inc. Cochleate compositions directed against expression of proteins
AU2004257149A1 (en) * 2003-06-20 2005-01-27 Coley Pharmaceutical Gmbh Small molecule toll-like receptor (TLR) antagonists
CA2536139A1 (en) * 2003-09-25 2005-04-07 Coley Pharmaceutical Group, Inc. Nucleic acid-lipophilic conjugates
CA2542099A1 (en) * 2003-10-11 2005-04-21 Inex Pharmaceuticals Corporation Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
SG123799A1 (en) 2003-10-30 2006-07-26 Coley Pharm Gmbh C-class oligonucleotide analogs with enchanced immunostimulatory potency
US20050239733A1 (en) * 2003-10-31 2005-10-27 Coley Pharmaceutical Gmbh Sequence requirements for inhibitory oligonucleotides
US20050100983A1 (en) * 2003-11-06 2005-05-12 Coley Pharmaceutical Gmbh Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling
WO2005097993A2 (en) * 2004-02-19 2005-10-20 Coley Pharmaceutical Group, Inc. Immunostimulatory viral rna oligonucleotides
WO2005082922A1 (en) 2004-02-26 2005-09-09 Layerlab Aktiebolag Oligonucleotides related to lipid membrane attachments
AU2005243250A1 (en) * 2004-04-02 2005-11-24 Coley Pharmaceutical Gmbh Immunostimulatory nucleic acids for inducing IL-10 responses
MY159370A (en) * 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
US20060134189A1 (en) * 2004-11-17 2006-06-22 Protiva Biotherapeutics, Inc siRNA silencing of apolipoprotein B
SG160336A1 (en) 2005-03-04 2010-04-29 Dynavax Tech Corp Vaccines comprising oligonucleotides having immunostimulatory sequences (iss) wherein the iss are conjugated to antigens and stabilized by buffer conditions and further excipients
MX2007012488A (es) * 2005-04-08 2008-03-11 Coley Pharm Group Inc Metodos para el tratamiento de asma exacerbado por enfermedad infecciosa.
US20060241076A1 (en) * 2005-04-26 2006-10-26 Coley Pharmaceutical Gmbh Modified oligoribonucleotide analogs with enhanced immunostimulatory activity
WO2007008463A2 (en) * 2005-07-07 2007-01-18 Coley Pharmaceutical Group, Inc. Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
US20070054873A1 (en) * 2005-08-26 2007-03-08 Protiva Biotherapeutics, Inc. Glucocorticoid modulation of nucleic acid-mediated immune stimulation
AU2006290435A1 (en) * 2005-09-16 2007-03-22 Coley Pharmaceutical Gmbh Modulation of immunostimulatory properties of short interfering ribonucleic acid (siRNA) by nucleotide modification
US20090214578A1 (en) * 2005-09-16 2009-08-27 Coley Pharmaceutical Gmbh Immunostimulatory Single-Stranded Ribonucleic Acid with Phosphodiester Backbone
AU2006308765B2 (en) 2005-11-02 2013-09-05 Arbutus Biopharma Corporation Modified siRNA molecules and uses thereof
CN102517292B (zh) 2005-11-25 2014-12-24 佐蒂斯比利时股份有限公司 免疫刺激性寡核糖核苷酸
DE102006007433A1 (de) * 2006-02-17 2007-08-23 Curevac Gmbh Adjuvanz in Form einer Lipid-modifizierten Nukleinsäure
US7915399B2 (en) * 2006-06-09 2011-03-29 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
WO2008014979A2 (en) 2006-07-31 2008-02-07 Curevac Gmbh NUCLEIC ACID OF FORMULA (I): GIXmGn, OR (II): CIXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT
AU2007284036A1 (en) * 2006-08-16 2008-02-21 Protiva Biotherapeutics, Inc. Nucleic acid modulation of Toll-like receptor-mediated immune stimulation
NZ575437A (en) * 2006-09-27 2012-02-24 Coley Pharm Gmbh Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity
US20090142362A1 (en) * 2006-11-06 2009-06-04 Avant Immunotherapeutics, Inc. Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (CETP)
PL2170353T3 (pl) * 2007-05-18 2015-10-30 Adiutide Pharmaceuticals Gmbh Modyfikowane fosforanami analogi oligonukleotydów wykazujące aktywność immunostymulującą
EP2591787A1 (en) 2007-08-13 2013-05-15 Pfizer Inc Combination motif immune stimulatory oligonucleotides with improved activity
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
CN101874111B (zh) * 2007-11-28 2013-06-05 国立大学法人东京医科齿科大学 利用内源性乳糜微粒递送用于抑制靶基因表达的核酸的体系
CA2710534C (en) 2008-01-31 2018-09-04 Curevac Gmbh Nucleic acids of formula (i) (nuglxmgnnv)a and derivatives thereof as an immunostimulating agent/adjuvant
US8846080B2 (en) * 2008-08-28 2014-09-30 Glaxosmithkline Biologicals S.A. Vaccine
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
WO2010067262A1 (en) 2008-12-09 2010-06-17 Pfizer Inc. Immunostimulatory oligonucleotides
US8552165B2 (en) * 2008-12-09 2013-10-08 Heather Davis Immunostimulatory oligonucleotides
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
US8883174B2 (en) 2009-03-25 2014-11-11 The Board Of Regents, The University Of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens
EP2427472B1 (en) 2009-05-05 2016-06-22 Miragen Therapeutics Lipophilic polynucleotide conjugates
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
ES2558106T3 (es) 2010-07-30 2016-02-02 Curevac Ag Formación de complejos de ácidos nucleicos con componentes catiónicos disulfuro-reticulados para la transfección e inmunoestimulación
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
WO2013067203A1 (en) 2011-11-02 2013-05-10 The Regents Of The University Of California Reprogramming of cellular adhesion
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
US9107904B2 (en) 2012-04-05 2015-08-18 Massachusetts Institute Of Technology Immunostimulatory compositions and methods of use thereof
NZ708171A (en) * 2012-11-15 2019-11-29 Roche Innovation Ct Copenhagen As Oligonucleotide conjugates
EP2971165A4 (en) 2013-03-15 2016-11-23 Moderna Therapeutics Inc DISSOLUTION OF DNA FRAGMENTS IN MRNA MANUFACTURING METHODS
US10590161B2 (en) 2013-03-15 2020-03-17 Modernatx, Inc. Ion exchange purification of mRNA
EP2971161B1 (en) 2013-03-15 2018-12-26 ModernaTX, Inc. Ribonucleic acid purification
EP2971033B8 (en) 2013-03-15 2019-07-10 ModernaTX, Inc. Manufacturing methods for production of rna transcripts
CA2908939C (en) 2013-05-01 2023-08-22 Balkrishen Bhat Microrna compounds and methods for modulating mir-122
WO2014179445A1 (en) 2013-05-01 2014-11-06 Regulus Therapeutics Inc. Compounds and methods for enhanced cellular uptake
LT3019619T (lt) 2013-07-11 2021-12-10 Modernatx, Inc. Sintetinius polinukleotidus apimančios kompozicijos, koduojančios susijusius su crispr baltymus ir sintetines sgrnas, ir jų naudojimo būdai
WO2015013673A1 (en) 2013-07-25 2015-01-29 Aurasense Therapeutics, Llc Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
WO2015023797A1 (en) 2013-08-13 2015-02-19 Northwestern University Lipophilic nanoparticles for drug delivery
AU2014310934B2 (en) 2013-08-21 2019-09-12 CureVac SE Respiratory syncytial virus (RSV) vaccine
US10182988B2 (en) 2013-12-03 2019-01-22 Northwestern University Liposomal particles, methods of making same and uses thereof
CA2936286A1 (en) 2014-04-01 2015-10-08 Curevac Ag Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
AU2015269412B2 (en) 2014-06-04 2020-03-12 Exicure Operating Company Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
US10286086B2 (en) 2014-06-19 2019-05-14 Modernatx, Inc. Alternative nucleic acid molecules and uses thereof
CA2955238A1 (en) 2014-07-16 2016-01-21 Moderna Therapeutics, Inc. Circular polynucleotides
US10286065B2 (en) 2014-09-19 2019-05-14 Board Of Regents, The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
JP2017537619A (ja) 2014-11-21 2017-12-21 ノースウェスタン ユニバーシティ 球状核酸ナノ粒子複合体の配列特異的細胞内取込
US11268098B2 (en) 2014-12-25 2022-03-08 National Institutes Of Biomedical Innovation, Health And Nutrition Non-aggregating immunostimulatory oligonucleotides
WO2017007027A1 (ja) * 2015-07-09 2017-01-12 国立研究開発法人物質・材料研究機構 免疫刺激オリゴヌクレオチド複合体
US11434486B2 (en) 2015-09-17 2022-09-06 Modernatx, Inc. Polynucleotides containing a morpholino linker
JP2018527003A (ja) 2015-09-17 2018-09-20 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 安定化尾部領域を含むポリヌクレオチド
WO2017193087A1 (en) 2016-05-06 2017-11-09 Exicure, Inc. Liposomal spherical nucleic acid (sna) constructs prsenting antisense oligonucleotides(aso) for specific knockdown of interleukin 17 receptor mrna
WO2017223176A1 (en) 2016-06-24 2017-12-28 Modernatx, Inc. Methods and apparatus for filtration
WO2018013924A1 (en) 2016-07-15 2018-01-18 Massachusetts Institute Of Technology Synthetic nanoparticles for delivery of immunomodulatory compounds
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
US20200248183A1 (en) * 2017-04-03 2020-08-06 Subbarao Nallagatla Tlr9-targeted spherical nucleic acids having potent antitumor activity
WO2018201090A1 (en) 2017-04-28 2018-11-01 Exicure, Inc. Synthesis of spherical nucleic acids using lipophilic moieties
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
CA3079157A1 (en) 2017-11-02 2019-05-09 Janssen Biopharma, Inc. Oligonucleotide constructs and uses thereof
SG11202004773SA (en) 2017-12-15 2020-06-29 Bayer Animal Health Gmbh Immunostimulatory compositions
TWI854980B (zh) 2018-05-08 2024-09-11 美商雷格勒斯治療公司 用於調節mir-122之微小rna化合物及方法
US12453777B2 (en) 2019-03-20 2025-10-28 Massachusetts Institute Of Technology Uses of amphiphiles in immune cell therapy and compositions therefor

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990014822A1 (en) * 1989-06-06 1990-12-13 Northwestern University Steroid modified oligonucleotides
WO1999062923A2 (en) * 1998-06-05 1999-12-09 Dynavax Technologies Corporation Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US6030955A (en) * 1996-03-21 2000-02-29 The Trustees Of Columbia University In The City Of New York And Imclone Systems, Inc. Methods of affecting intracellular phosphorylation of tyrosine using phosphorothioate oligonucleotides, and antiangiogenic and antiproliferative uses thereof
US6194388B1 (en) * 1994-07-15 2001-02-27 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6949520B1 (en) * 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon

Family Cites Families (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0092574B1 (en) 1981-10-23 1992-04-29 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and methods of making same
US4541087A (en) * 1983-06-27 1985-09-10 Confertech International, Inc. Digital teleconferencing control device, system and method
CA1339596C (en) 1987-08-07 1997-12-23 New England Medical Center Hospitals, Inc. Viral expression inhibitors
US5399676A (en) * 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
AU678769B2 (en) * 1992-07-27 1997-06-12 Hybridon, Inc. Oligonucleotide alkylphosphonothioates
US5558988A (en) * 1992-11-13 1996-09-24 Thomas Jefferson University Primers and methods for detecting mutations in the procollagen II gene that indicate a genetic predisposition for osteoarthritis
US6605708B1 (en) 1993-07-28 2003-08-12 Hybridon, Inc. Building blocks with carbamate internucleoside linkages and oligonucleotides derived therefrom
DE4338704A1 (de) * 1993-11-12 1995-05-18 Hoechst Ag Stabilisierte Oligonucleotide und deren Verwendung
US5646126A (en) * 1994-02-28 1997-07-08 Epoch Pharmaceuticals Sterol modified oligonucleotide duplexes having anticancer activity
US5596091A (en) * 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US6727230B1 (en) * 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030050263A1 (en) 1994-07-15 2003-03-13 The University Of Iowa Research Foundation Methods and products for treating HIV infection
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6429199B1 (en) * 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
DE19502912A1 (de) 1995-01-31 1996-08-01 Hoechst Ag G-Cap Stabilisierte Oligonucleotide
US5968909A (en) 1995-08-04 1999-10-19 Hybridon, Inc. Method of modulating gene expression with reduced immunostimulatory response
US5780448A (en) * 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
US7432048B2 (en) * 1996-11-29 2008-10-07 Third Wave Technologies, Inc. Reactions on a solid surface
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
WO1998016247A1 (en) 1996-10-11 1998-04-23 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
EP0855184A1 (en) * 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
EP1039935A4 (en) * 1997-02-28 2005-04-27 Univ Iowa Res Found USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6426334B1 (en) 1997-04-30 2002-07-30 Hybridon, Inc. Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
US6835395B1 (en) 1997-05-14 2004-12-28 The University Of British Columbia Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles
AU7690898A (en) 1997-05-20 1998-12-11 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
US6589940B1 (en) * 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US20040006034A1 (en) * 1998-06-05 2004-01-08 Eyal Raz Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
DE69819150T3 (de) 1997-06-06 2007-12-20 Dynavax Technologies Corp., San Diego Immunstimulierende oligonucleotide, zusammensetzungen davon, und verfahren zur verwendung davon
EP1009440B1 (en) * 1997-07-03 2008-09-17 MacFarlane, Donald E. Method for inhibiting immunostimulatory dna associated responses
DE19750702A1 (de) * 1997-11-15 1999-05-27 Hoechst Marion Roussel De Gmbh Antisense Oligonucleotide gegen Tenascin zur Behandlung von Vitiligo
US7393630B2 (en) * 1997-12-16 2008-07-01 Novartis Vaccines And Diagnostics, Inc. Use of microparticles combined with submicron oil-in-water emulsions
EP1067956B1 (en) * 1998-04-03 2007-03-14 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
EP1595946A3 (en) * 1998-04-14 2006-01-11 Sugen, Inc. STE20-related protein kinases
ES2248997T3 (es) * 1998-04-14 2006-03-16 Sugen, Inc. Proteina-quinasas ste20-relacionadas.
EP1077708A1 (en) 1998-05-06 2001-02-28 University Of Iowa Research Foundation Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
ATE305507T1 (de) 1998-05-14 2005-10-15 Coley Pharm Gmbh Verfahren zur regulierung der hematopoiese mit hilfe von cpg oligonukleotide
CA2328894A1 (en) 1998-05-22 1999-12-02 Loeb Health Research Institute At The Ottawa Hospital Methods and products for inducing mucosal immunity
CA2333854A1 (en) 1998-07-27 2000-02-10 University Of Iowa Research Foundation Stereoisomers of cpg oligonucleotides and related methods
DE69943392D1 (de) * 1998-08-20 2011-06-09 Du Pont Gene für fettsäuremodfizierende enzyme von planzen und damit verbundene bildung von konjugierten doppelbindungen
FR2783170B1 (fr) 1998-09-11 2004-07-16 Pasteur Merieux Serums Vacc Emulsion immunostimulante
WO2000030655A1 (en) * 1998-11-20 2000-06-02 Bristol-Myers Squibb Company Water soluble prodrugs of azole compounds
US6207819B1 (en) * 1999-02-12 2001-03-27 Isis Pharmaceuticals, Inc. Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds
WO2000054803A2 (en) 1999-03-16 2000-09-21 Panacea Pharmaceuticals, Llc Immunostimulatory nucleic acids and antigens
US6977245B2 (en) * 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
WO2000061151A2 (en) * 1999-04-12 2000-10-19 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
EP1377554A1 (en) 1999-06-16 2004-01-07 University Of Iowa Research Foundation Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases
US6514948B1 (en) * 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
DE19935756A1 (de) * 1999-07-27 2001-02-08 Mologen Forschungs Entwicklung Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation
DE19935302A1 (de) * 1999-07-28 2001-02-08 Aventis Pharma Gmbh Konjugate und Verfahren zu deren Herstellung sowie deren Verwendung zum Transport von Molekülen über biologische Membranen
US6822086B1 (en) * 1999-08-09 2004-11-23 The General Hospital Corporation Drug-carrier complexes and methods of use thereof
DK1200580T3 (da) 1999-08-13 2005-04-11 Hybridon Inc Modulering af oligonukleotid-CpG-medieret immunstimulering ved positionel modifikation
NZ517929A (en) 1999-09-25 2004-02-27 Univ Iowa Res Found Immunostimulatory nucleic acids
ATE378348T1 (de) * 2000-01-14 2007-11-15 Us Health Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion
WO2001095935A1 (en) 2000-01-20 2001-12-20 Ottawa Health Research Institute Immunostimulatory nucleic acids for inducing a th2 immune response
EP1252307B1 (en) 2000-01-26 2008-01-02 Idera Pharmaceuticals, Inc. MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES
US7585847B2 (en) 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
US20020156033A1 (en) 2000-03-03 2002-10-24 Bratzler Robert L. Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer
US20040131628A1 (en) * 2000-03-08 2004-07-08 Bratzler Robert L. Nucleic acids for the treatment of disorders associated with microorganisms
JP3585420B2 (ja) * 2000-04-20 2004-11-04 株式会社椿本チエイン チェーン用巻き加工品及びその製造方法
US20020013287A1 (en) 2000-05-09 2002-01-31 Reliable Biopharmaceuticals, Inc. St Louis Missouri Polymeric compounds useful as prodrugs
US6339630B1 (en) * 2000-05-18 2002-01-15 The United States Of America As Represented By The United States Department Of Energy Sealed drive screw operator
DE60139689D1 (de) * 2000-06-22 2009-10-08 Univ Iowa Res Found Kombination von CpG und Antikörpern gegen CD19,CD20,CD22 oder CD40 zur Prävention oder Behandlung von Krebs.
US20020165178A1 (en) 2000-06-28 2002-11-07 Christian Schetter Immunostimulatory nucleic acids for the treatment of anemia, thrombocytopenia, and neutropenia
US20020198165A1 (en) 2000-08-01 2002-12-26 Bratzler Robert L. Nucleic acids for the prevention and treatment of gastric ulcers
US20020091097A1 (en) * 2000-09-07 2002-07-11 Bratzler Robert L. Nucleic acids for the prevention and treatment of sexually transmitted diseases
WO2002022809A2 (en) * 2000-09-15 2002-03-21 Coley Pharmaceutical Gmbh PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST
JP2004509970A (ja) 2000-09-26 2004-04-02 ハイブリドン・インコーポレイテッド 位置的化学変化による免疫刺激オリゴヌクレオチドアナログの免疫刺激活性の調節
FR2814958B1 (fr) * 2000-10-06 2003-03-07 Aventis Pasteur Composition vaccinale
GB0025577D0 (en) * 2000-10-18 2000-12-06 Smithkline Beecham Biolog Vaccine
DE60134421D1 (de) 2000-12-08 2008-07-24 Coley Pharmaceuticals Gmbh Cpg-artige nukleinsäuren und verfahren zu ihrer verwendung
US20030055014A1 (en) * 2000-12-14 2003-03-20 Bratzler Robert L. Inhibition of angiogenesis by nucleic acids
US20030050268A1 (en) * 2001-03-29 2003-03-13 Krieg Arthur M. Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
US20030052063A1 (en) * 2001-03-30 2003-03-20 Motoaki Sakashita Decontamination method and apparatus
US7713942B2 (en) * 2001-04-04 2010-05-11 Nordic Vaccine Technology A/S Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
US7105495B2 (en) 2001-04-30 2006-09-12 Idera Pharmaceuticals, Inc. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
US7785610B2 (en) * 2001-06-21 2010-08-31 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same—III
US20040132677A1 (en) * 2001-06-21 2004-07-08 Fearon Karen L. Chimeric immunomodulatory compounds and methods of using the same-IV
DK2423335T3 (da) 2001-06-21 2014-08-18 Dynavax Tech Corp Kimæriske immunmodulatoriske forbindelser og fremgangsmåder til anvendelse deraf
US6893572B2 (en) * 2001-07-12 2005-05-17 Western Environmental Engineering Company Solids accumulating flotation separator
WO2003040308A2 (en) * 2001-07-27 2003-05-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver cpg oligonucleotides in vivo
US7666674B2 (en) * 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
US20030148316A1 (en) 2001-08-01 2003-08-07 Lipford Grayson B. Methods and compositions relating to plasmacytoid dendritic cells
WO2003020884A2 (en) * 2001-08-14 2003-03-13 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Method for rapid generation of mature dendritic cells
JP4383534B2 (ja) 2001-08-17 2009-12-16 コーリー ファーマシューティカル ゲーエムベーハー 改善した活性を有する組み合わせモチーフ免疫刺激オリゴヌクレオチド
JP4190005B2 (ja) * 2001-08-22 2008-12-03 株式会社抗体研究所 結合性分子の選択方法
ATE451935T1 (de) * 2001-09-28 2010-01-15 Purdue Research Foundation Behandlungsverfahren mit liganden- immunogenkonjugaten
JP2005505284A (ja) 2001-10-05 2005-02-24 コリー ファーマスーティカル ゲーエムベーハー Ｔｏｌｌ様受容体３シグナリングアゴニストおよびアンタゴニススト
US20030139364A1 (en) * 2001-10-12 2003-07-24 University Of Iowa Research Foundation Methods and products for enhancing immune responses using imidazoquinoline compounds
US7276489B2 (en) * 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
AU2002366710A1 (en) * 2001-12-20 2003-07-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
US7741297B2 (en) 2002-02-04 2010-06-22 Oncothyreon Inc. Immunostimulatory, covalently lipidated oligonucleotides
WO2003086280A2 (en) 2002-04-04 2003-10-23 Coley Pharmaceutical Gmbh Immunostimulatory g,u-containing oligoribonucleotides
CN101160399A (zh) * 2002-04-22 2008-04-09 拜奥尼茨生命科学公司 寡核苷酸组合物及其在调节免疫应答中的应用
WO2003094963A2 (en) 2002-05-10 2003-11-20 Inex Pharmaceuticals Corporation Methylated immunostimulatory oligonucleotides and methods of using the same
US20040009949A1 (en) * 2002-06-05 2004-01-15 Coley Pharmaceutical Group, Inc. Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory CpG nucleic acids
US7569553B2 (en) * 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) * 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) * 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
WO2004007743A2 (en) 2002-07-17 2004-01-22 Coley Pharmaceutical Gmbh Use of cpg nucleic acids in prion-disease
WO2004014322A2 (en) * 2002-08-12 2004-02-19 Dynavax Technologies Corporation Immunomodulatory compositions, methods of making, and methods of use thereof
AR040996A1 (es) * 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
US8043622B2 (en) * 2002-10-08 2011-10-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides
CN101948835A (zh) * 2002-10-29 2011-01-19 科勒制药集团股份有限公司 Cpg寡核苷酸在治疗丙型肝炎病毒感染中的应用
EP1572122A4 (en) * 2002-11-01 2008-04-09 Us Gov Health & Human Serv METHOD FOR PREVENTING INFECTIONS OF BIOTERRORISM AGENTS WITH IMMUNOSTIMULATING CPG OLIGONUCLEOTIDES
AU2003300919A1 (en) 2002-12-11 2004-06-30 Coley Pharmaceutical Gmbh 5' cpg nucleic acids and methods of use
WO2004058159A2 (en) * 2002-12-23 2004-07-15 Dynavax Technologies Corporation Branched immunomodulatory compounds and methods of using the same
AU2004206820B2 (en) * 2003-01-16 2010-06-10 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
AU2004226605A1 (en) * 2003-04-02 2004-10-14 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations for topical application
WO2004094671A2 (en) 2003-04-22 2004-11-04 Coley Pharmaceutical Gmbh Methods and products for identification and assessment of tlr ligands
KR101137572B1 (ko) * 2003-06-11 2012-05-30 이데라 파마슈티칼즈, 인코포레이티드 안정화된 면역조절 올리고뉴클레오티드
AU2004257149A1 (en) * 2003-06-20 2005-01-27 Coley Pharmaceutical Gmbh Small molecule toll-like receptor (TLR) antagonists
JP2007531699A (ja) * 2003-07-15 2007-11-08 イデラ ファーマシューティカルズ インコーポレイテッド 免疫刺激性オリゴヌクレオチドおよび／またはイムノマー化合物をサイトカインおよび／または化学療法剤または放射線療法と組み合わせて用いる、免疫系の相乗的刺激
WO2005025583A2 (en) * 2003-09-05 2005-03-24 Anadys Pharmaceuticals, Inc. Tlr7 ligands for the treatment of hepatitis c
CA2536139A1 (en) * 2003-09-25 2005-04-07 Coley Pharmaceutical Group, Inc. Nucleic acid-lipophilic conjugates
US20050215501A1 (en) 2003-10-24 2005-09-29 Coley Pharmaceutical Group, Inc. Methods and products for enhancing epitope spreading
SG123799A1 (en) * 2003-10-30 2006-07-26 Coley Pharm Gmbh C-class oligonucleotide analogs with enchanced immunostimulatory potency
US20050100983A1 (en) * 2003-11-06 2005-05-12 Coley Pharmaceutical Gmbh Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling
EP1699814A4 (en) * 2003-12-08 2009-01-14 Hybridon Inc MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF COMPOUNDS FORMED FROM SMALL OLIGONUCLEOTIDES
CA2567789A1 (en) * 2004-06-08 2006-08-03 Coley Pharmaceutical Gmbh Abasic oligonucleotide as carrier platform for antigen and immunostimulatory agonist and antagonist
WO2006002038A2 (en) * 2004-06-15 2006-01-05 Hybridon, Inc. Immunostimulatory oligonucleotide multimers
JP2008506683A (ja) * 2004-07-18 2008-03-06 コーリー ファーマシューティカル グループ， リミテッド 先天免疫応答を誘導するための方法および組成物
MY159370A (en) * 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
ATE521621T1 (de) * 2004-11-29 2011-09-15 Changchun Huapu Biotechnology Co Ltd Cpg-einzelstrang-desoxynukleotide zur verwendung als adjuvans
CN1810970B (zh) * 2005-01-27 2011-05-18 长春华普生物技术有限公司 含CpG的单链脱氧核苷酸与其疫苗组合物及其应用
CN1847256B (zh) * 2005-04-13 2011-06-15 长春华普生物技术有限公司 含CpG单链脱氧寡核苷酸和利巴韦林联合应用产生的抗病毒作用
US7792535B2 (en) * 2005-05-31 2010-09-07 Alcatel-Lucent Usa Inc. Enhanced mobile station paging in a wireless telecommunications network
WO2007008463A2 (en) * 2005-07-07 2007-01-18 Coley Pharmaceutical Group, Inc. Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
US7965675B2 (en) * 2005-08-22 2011-06-21 Motorola Mobility, Inc. System and method for detecting an unlicensed mobile alliance (UMA) service in GSM wireless communication networks
US7892569B2 (en) * 2005-08-31 2011-02-22 The United States Of America As Represented By The Department Of Health And Human Services Methods of altering an immune response induced by CpG oligodeoxynucleotides
US8399423B2 (en) * 2005-10-12 2013-03-19 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
CN102517292B (zh) * 2005-11-25 2014-12-24 佐蒂斯比利时股份有限公司 免疫刺激性寡核糖核苷酸
CA2642152C (en) * 2006-02-15 2016-11-01 Coley Pharmaceutical Gmbh Compositions and methods for oligonucleotide formulations
EP2021008B1 (en) * 2006-04-07 2015-12-02 Idera Pharmaceuticals, Inc. Stabilized immune modulatory rna (simra) compounds for tlr7 and tlr8
NZ575437A (en) * 2006-09-27 2012-02-24 Coley Pharm Gmbh Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity
US8377898B2 (en) * 2006-10-12 2013-02-19 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
WO2008070666A2 (en) * 2006-12-04 2008-06-12 The Board Of Trustees Of The University Of Illinois Compositions and methods to treat cancer with cpg rich dna and cupredoxins
EP2821488B1 (en) * 2007-08-01 2016-07-27 Idera Pharmaceuticals, Inc. Novel synthetic agonists of TLR9
EP2591787A1 (en) * 2007-08-13 2013-05-15 Pfizer Inc Combination motif immune stimulatory oligonucleotides with improved activity
CA2704853C (en) * 2007-11-06 2017-08-15 Eugen Uhlmann Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties
CN102388139A (zh) * 2008-11-04 2012-03-21 艾德拉药物股份有限公司 通过反义寡核苷酸来调制Toll样受体5表达

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990014822A1 (en) * 1989-06-06 1990-12-13 Northwestern University Steroid modified oligonucleotides
US6194388B1 (en) * 1994-07-15 2001-02-27 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6030955A (en) * 1996-03-21 2000-02-29 The Trustees Of Columbia University In The City Of New York And Imclone Systems, Inc. Methods of affecting intracellular phosphorylation of tyrosine using phosphorothioate oligonucleotides, and antiangiogenic and antiproliferative uses thereof
WO1999062923A2 (en) * 1998-06-05 1999-12-09 Dynavax Technologies Corporation Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US6949520B1 (en) * 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
HARTMANN, G. et al., PNAS. 1999, vol. 96, pages 9305-10 (Y) *
KRIEG, A.M. et al., NATURE, 1995, vol. 374, pages 546-49 (Y) *
LETSINGER, R. L. et al., NUCLEIC ACIDS SYMPOSIUM SERIES, 1991, no. 24, pages 75-78 (Y) *
LETSINGER, R.L. et al., PNAS. 1989, vol. 86, no. 17, pages 6553-56 (Y) *
MACKELLAR, C. et al., NUCLEIC ACIDS RESEARCH, 1992, vol. 13, no. 20, pages 3411-17 (Y) *
POLANCZYK, M. et al., 2000,vol. 25, no. 3, pages 160-66 (Y) *

Also Published As

Publication number Publication date
US7615539B2 (en) 2009-11-10
EP1663316A2 (en) 2006-06-07
CA2536139A1 (en) 2005-04-07
WO2005030259A3 (en) 2005-11-10
JP2007506790A (ja) 2007-03-22
US20100183639A1 (en) 2010-07-22
WO2005030259A2 (en) 2005-04-07
JP4989225B2 (ja) 2012-08-01
AU2004275876A1 (en) 2005-04-07
US20050130911A1 (en) 2005-06-16

Similar Documents

Publication Publication Date Title
AU2004275876B2 (en) Nucleic acid-lipophilic conjugates
US8188254B2 (en) C-class oligonucleotide analogs with enhanced immunostimulatory potency
US7956043B2 (en) 5′ CpG nucleic acids and methods of use
ES2634328T3 (es) Ácidos nucleicos inmunoestimuladores
US9382545B2 (en) CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity
US20080009455A9 (en) Immunostimulatory oligonucleotides
US20110098456A1 (en) Immune stimulatory oligonucleotide analogs containing modified sugar moieties
HK1098785A (en) C-class oligonucleotide analogs with enhanced immunostimulatory potency

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired